Aspen Neuroscience, Inc.
Aspen Neuroscience, a clinical-stage regenerative medicine biotech, filed an amended S-1 for its proposed IPO on Nasdaq under ticker "ASPE." The company's lead candidate, sasineprocel, is an autologous iPSC-derived dopaminergic neuron precursor cell therapy for Parkinson's disease currently in a Phase 1/2a ASPIRO trial. As of the August 18, 2026 data cutoff, 15 patients had been dosed across four cohorts, with sustained motor and quality-of-life improvements observed at 18 and 24 months above clinically meaningful change benchmarks. The offering is underwritten by Leerink Partners, UBS, Piper,
- Lead candidate sasineprocel is in an ongoing Phase 1/2a ASPIRO trial with 15 patients dosed as of August 18, 2026.
- Sasineprocel has RMAT and Fast Track designations from the FDA for Parkinson's disease.
- Mean improvements at 18 months in Good On Time and MDS-UPDRS Part III OFF exceeded clinically meaningful change benchmarks.
- The autologous iPSC approach requires no immunosuppression post-administration, unlike allogeneic competitors.
- Phase 3 biopsy collection expected by end of 2026; Phase 3 dosing anticipated in the second half of 2027.
Price data unavailable.
A clinical-stage biotech with positive open-label Parkinson's data, RMAT/Fast Track designations, and a differentiated autologous no-immunosuppression platform is heading to public markets.
Aspen enters a competitive CNS cell-therapy landscape alongside allogeneic PD programs from BlueRock Therapeutics (Bayer) and others. Its autologous, no-immunosuppression approach is a key differentiator but adds manufacturing complexity and per-patient cost versus off-the-shelf allogeneic therapies
The ASPIRO trial is open-label with no placebo or control cohort, limiting interpretability of efficacy data. The clinically meaningful change benchmarks have not been discussed with the FDA or independently validated. No assurance RMAT/Fast Track designations will accelerate approval.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.